Statement of translational relevance
In the era of targeted molecular therapies, intratumor heterogeneity is an emerging challenge to successful cancer therapy since it may result in evasion of therapy of distinct cell subpopulations or in development of therapy resistance as an adaptive phenomenon to specific inhibiting therapies. Therefore, investigating the frequency of and comprehensively characterizing intratumor heterogeneity is crucial. In hepatocellular carcinoma (HCC), it is known that tumors can display intratumoral heterogeneous morphology and histological differentiation grades. In our study we aimed to make a link between morphological intratumor heterogeneity, immune phenotypes (CK7, CD44, AFP, EpCAM, glutamine synthetase) and genetic heterogeneity of the two most important driver mutations in HCC (CTNNB1 and TP53), of which β-catenin (CTNNB1) represents a potential therapeutic target.
We used multiregional sequencing, supplementing Sanger sequencing with next generation sequencing which added a high level of accuracy to our analyses. Our results illustrate that intratumor heterogeneity is a frequent finding in HCC, which has implications not only for targeted therapies but also for establishing a robust HCC classification in daily clinical practice.
Introduction
Hepatocellular carcinoma (HCC) generally arises in the context of chronic liver diseases, including chronic viral hepatitis, alcohol-induced liver injury, or other metabolic, dietary or toxic factors such as fatty liver disease or aflatoxin ingestion [1] and ranks number three among the leading causes of cancer mortality worldwide [2] . It is worthy of note that dietary induced liver cancer is one the fastest growing cancer in the United States of America [3] .
For a pathologic stratification, tumor stage and grade are the only valid prognostic factors to date. Attempts to classify HCC by immunohistochemical markers or molecular genetic characteristics added fundamental knowledge to our understanding of hepatocarcinogenesis, but so far have hardly been applied in routine surgical pathology and postoperative management [4, 5] . This stands in contrast to the widely accepted classification of hepatocellular adenoma based on morphology, immunohistochemistry and genetics that has been included in the latest edition of the WHO classification [6, 7] , and has implications for patient management.
It is well-known that HCC frequently display heterogeneous growth patterns and/or cytological features within one and the same tumor. This might either reflect plasticity of phenotypes or intratumor genetic heterogeneity. Both have been described in several solid tumor entities, including skin, breast, and kidney cancer [8] [9] [10] [11] [12] . In small HCC, intratumor heterogeneity with respect to histological differentiation grade and proliferative activity was reported to occur in up to 64% of HCC measuring 3-5 cm in diameter and in 25-47% of HCC smaller than 2 cm [13, 14] . Nonetheless, especially in larger HCC the true extent of intratumor heterogeneity with respect to morphological, immunohistochemical and molecular features has not been systematically assessed. The aim of this study was to systematically investigate intratumor heterogeneity in HCC by a comprehensive analysis of tumor areaspecific morphology, correlated with clinically relevant immunohistochemical markers [15] [16] [17] [18] [19] [20] [21] .
CK7 is a marker of biliary as well as progenitor cell differentiation. CK7/19, in conjunction with TP53 mutations, has been described as a marker of putative HCC progenitor cells [15] and its expression has been correlated to early tumor recurrence [22] . Likewise, CD44,
Research. EpCAM and AFP have been described to be expressed in hepatic progenitor cells and/or hepatocellular carcinoma [18] [19] [20] [21] . In addition, AFP is a serum marker for HCC [23] . The enzyme glutamine synthetase (GS), a marker of pericentral nonneoplastic hepatocytes, is an indicator of Wnt signaling, and together with nuclear accumulation of β-catenin a surrogate marker for CTNNB1 gene mutations [17, 24] . Analyses were supplemented by multiregional amplicon sequencing of the two genes most frequently mutated in HCC, TP53 and CTNNB1 (β-catenin) [5, 23, 25, 26] .
Material and Methods

Patients and tissues
23 patients with an initial diagnosis of a primary hepatocellular carcinoma (HCC) receiving surgical treatment between 2003 and 2009 at the University Hospital Zurich were included in this study. Excluded were cases with any kind of pretreatment (e.g. chemotherapy, TACE) and cases with substantial tumor necrosis (>20%). Necrotic tumor areas, ranging between 3-20%, were not included in the analyses. Tumor and adjacent normal liver tissues were formalin-fixed, paraffin embedded (FFPE) and cut into 2-3 µm sections. Histologic slides were stained with hematoxylin & eosin and scanned with a Hamamatsu NDPI Nano Zoomer (Hamamatsu, Japan 18 cm was arbitrarily divided into large (>4cm, n=14) and smaller HCC (<4cm, n=9). The following criteria were used to define specific intratumor areas on HE slides: intratumor fibrotic septa, "nodule-in-nodule" growth and different clearly demarcated architectural growth patterns. In HCC >4cm up to three tumor blocks were analyzed. At least one area was defined per block, resulting in a minimum of 3 analyzed intratumor regions per large HCC. In smaller HCC (<4cm), 3 areas per tumor from one tumor block were analyzed. Tumor satellite nodules were excluded from the analysis.
The architectural growth patterns of individual tumor areas (solid, pseudoglandular and trabecular) were defined according to the WHO classification 2009 [1] . Additionally, the presence of typical cytological features such as clear cell aspect, fatty change and pleomorphic cells was analyzed. The morphology was designated as heterogeneous if different architectural pattern and/or cytologic features were detectable within the same tumor.
Microdissection of the defined tumor areas was performed by punching two 0.6 mm cores from FFPE tissue blocks with a tissue micro-arrayer (Estigen, MTA1). To minimize potential wild type contamination, dissection marks of every tumor block were evaluated after the dissection procedure by cutting 30 consecutive sections, followed by additionally staining the last slide of every series.
Immunohistochemistry
All slides were stained with antibodies against cytokeratin 7 (CK7), cytokeratin 19 (CK19), CD34, CD44, epithelial cell adhesion molecule (EpCAM), α-fetoprotein (AFP), β-catenin and glutamine synthetase (GS), a downstream target of β-catenin [28, 29] individual pretreatments (GS: CC1 mild, CK7: Protease 4`). All other stainings (Ventana GX and Ventana Bench Mark Ultra) were performed as single stainings: CD34 (Ventana ultra view, CC1 mild), CD44 (Ventana ultra view, CC1 8`), AFP (Ventana opti view, CC1 mild), CK 19 (Ventana ultra view, P1 4`), and β-catenin (Ventana ultra view, CC1 mild).
A two point score was applied for glutamine synthetase (negative vs. positive) and for β-catenin (nuclear vs. non-nuclear staining). For CK7, CK19, CD34, CD44 and AFP staining, the percentage of immunoreactive cells with respect to each tumor area was semiquantitatively evaluated and grouped according to previously described scoring systems [15] > 50 % positive cells, 5 -50 % positive cells, < 5 % positive cells (also referred to as scattered cells) or negative. Intratumor expression was considered heterogeneous if expression intensities ranged from "negative" to "positive" (for glutamine synthetase), from "nuclear" to "non-nuclear" (for β-catenin) or from "negative" to > 5% positive cells (CK7, CK19, AFP, CD34, CD44). All staining intensities were compared to peritumoral liver tissue.
Morphology and immunohistochemistry results were evaluated by at least two different pathologists (JF and LF or AW).
DNA extraction and Sanger sequencing
DNA was extracted from the microdissected tumor areas using a DNA extraction and purification kit adapted for FFPE samples (NucleoSpin, FFPE DNA, Machery-Nagel and GFX PCR purification, GE healthcare). For amplification of exon 5-8 of the TP53 gene oligonucleotide primer pairs were used as described [30] . PCR was performed in a total volume of 50 µl with 100-150 ng purified tumor DNA, 0.2 mM dNTPs, 2.5 mM MgCl 2 , 400nM primer mix (forward and reverse), and 1 unit Taq-polymerase (Amplitaq Gold, Applied Biosystems). The S1000 Bio-Rad thermocycler (Bio-Rad laboratories, Cressier, Switzerland) was used for amplification (95°C initial denaturation, 5min; 40 cycles of 58°C annealing for was performed on an ABI 3130 xl DNA analyzer (Applied Biosystems). Sequences were analyzed using Bioedit software and BLAST http://blast.ncbi.nlm.nih.gov/Blast.cgi. Mutations were identified by comparison with reference sequences (CTNNB1-NM_1904.1, TP53-NM_001126112.2) and described according international conventions [31] .
HCC that showed intratumor heterogeneity on the molecular level by Sanger sequencing were additionally re-sequenced by deep sequencing on a 454 Junior Sequencer platform (Roche, Basel, Switzerland).
DNA quantification and amplicon library preparation for deep sequencing
Amplicon library preparation started with the target specific amplification using bidirectional fusion primers as described earlier [30] . CTNNB1 fusion primers were designed using 
Deep sequencing workflow and analysis
For the target regions exon 3 of CTNNB1 and exons 5-8 of TP53, deep sequencing was performed on a 454 Junior Sequencer (Roche, Basel, Switzerland). Demultiplexing, gene mapping and variant calling (reference genome GRch37/hg19) were performed with Amplicon Variant Analyser software (AVA) version 2.7 from Roche with default settings. We included variants that were present in forward and reverse sequences and with at least 50 reads for further analysis [30] . For quality control (sensitivity and specificity) we amplified the target regions from independent samples of FFPE extracted tumor DNA and sequenced each in an individual run. This resulted in 8 independently amplified and sequenced
replicates. In this re-sequenced control we detected the TP53 variant p.E258V in six of seven runs (sensitivity). The background error rate or "noise" (specificity) was calculated from the frequencies of unexpected single nucleotide changes, insertions or deletions with very low frequencies and/or strand bias that were detected in only one of seven replicate analyses (Supplementary figure 1) . One single nucleotide change with a strand bias (fw/rev ratio 2.3) located at a stretch of 4-homopolymers most probably represented a false positive call. As a result the calculated error rate of our control was 1.3% over all amplicons. Variants that could only be detected in deep sequencing and not in Sanger sequencing, i.e. < 10% frequency, were carefully analyzed for strand biases and coverage: if the minimum coverage of an identified variant was <1000 or had a strand bias > 1.5, these areas were re-sequenced.
To determine single nucleotide variants and the pathogenicity of mutations, every variant was annotated with an algorithm using free access databases. Annotations were taken from:
ENSEMBL (www.ensembl.org), mutations assessor (www.mutationassessor.org), Polyphen
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Results
Overall frequency of intratumor heterogeneity in hepatocellular carcinoma
In 23 
Three tumors were homogeneous, meaning that there was no variation in morphology or immunohistochemical marker expression within the tumor.
Clinico-pathological findings
The mean age of the patients was 62 years (SD +/-12.4), and the male/female ratio was 3.8/1. The mean size of the tumors (range 0.5-18cm) was 7.4cm SD +/-5.4cm. Large HCC (n=14) had a mean tumor size of 10 cm (SD+/-4) and small HCC (n=9) had a mean tumor size of 2 cm (SD +/-0.7). Table 1 
Intratumor heterogeneity of immune phenotypes Table 2 provides a heatmap of intratumor heterogeneity of immune phenotypes. Eleven tumors were glutamine synthetase positive and/or showed β-catenin nuclear positivity in at least one tumor area. The association between these two markers was in line with published data [24, 29] and found to be statistically significant (p=.006). Consistent glutamine synthetase positivity in all areas of the same tumor was found in only 2 cases, whereas heterogeneous immunoreactivity of glutamine synthetase was seen in 80% of the tumors S37 and two shared mutations (T41 and 15bp deletion at c.352-c.367) , while a single nucleotide polymorphism in exon 6 of TP53 (rs 1800372) was detected in all tumor areas.
Intratumor diversity of CTNNB1 and TP53 mutational status in HCC
Of 23 HCC, six were CTNNB1 mutated and two were TP53 mutated. CTNNB1 mutations affected the GSK-3β phosphorylation sites, as described [25] , and were significantly associated with immunohistochemical positivity for glutamine synthetase (p=.002) as well as nuclear accumulation of β-catenin (p=.009). Area-based analysis of mutational status, the expression of immunohistochemical markers and morphology revealed a positive association between CTNNB1 mutations, nuclear β-catenin [24] and glutamine synthetase positivity [29] . CTNNB1 mutations and AFP positivity were inversely associated as has been observed before [32] . Furthermore, a pseudoglandular growth pattern was frequently seen in CTNNB1 mutated tumor areas (45%). CD44 positivity was present in 70% of TP53 mutated areas [33] . The association between TP53 mutation and β-catenin immunohistochemistry found in our cohort was due to a single TP53 mutated HCC (patient 4) with nuclear β-catenin staining in all tumor areas (table 3) .
Discussion
In this study we systematically characterized intratumor heterogeneity in hepatocellular Morphological intratumor heterogeneity in HCC has been reported before by Kenmochi et al. [13] , who found two or more histological differentiation grades in more than half of the cases they had studied. An and coworkers [14] also analyzed heterogeneity with respect to the histological grade and described different tumor grades in 11 of 41 surgically resected small HCC (< 3 cm in diameter). After studying tumor heterogeneity on three different levels, we now confirm and further define this phenomenon, having detected heterogeneity in different combinations revealing a strict hierarchy: 1) either only on the level of morphology, 2) or morphological heterogeneity combined with immunohistochemical heterogeneity, 3) or a three feature intratumor heterogeneity with respect to morphology, immunohistochemistry and the mutational status of TP53 and CTNNB1. Morphological and immunophenotypical heterogeneity within a tumor might either reflect variable genetic aberrations or tumor cell plasticity without underlying genetic differences. Our data suggest that both apply to HCC.
Notably, about 50% of HCC reveal heterogeneous expression of two key immunohistochemical markers in liver pathology, i.e. CK7 and glutamine synthetase (GS), respectively, which also are used for HCC classification and prognostication [15] . Not unexpectedly, we observed that the frequency of morphological intratumor heterogeneity was associated with larger tumor size and higher tumor stage, although it did not reach statistical significance, most likely due to a small sample size.
Studying TP53 and CTNNB1, we found a heterogeneous intratumor mutational status in 22% of HCC. Different types of CTNNB1 mutations in one tumor sample were also reported before by Van Nieuh et al. [34] and Huang et al. [35] . Park et al. analyzed HCC as well as precursor lesions for the presence of CTNNB1 mutations, and found no CTNNB1 mutations in precursor lesions of HCC [36] . These findings show that CTNNB1 mutations, generally considered as driver mutations in HCC, are not uniformly present in all tumor regions within the same tumor, and reflect a rather late event in hepatocarcinogenesis. TP53 and CTNNB1 are both used as molecular classifiers for hepatocellular carcinoma [26, 37] . For instance, the transcriptome classification proposed by Boyault et al. depicts 6 subgroups of HCC; two groups are associated with TP53 and two other groups with CTNNB1 alterations [37] . The intratumor heterogeneity we found on the molecular and morphological level indicates a high degree of genetic instability in HCC. This stands in contrast to hepatocellular adenoma, for
Research. [38, 39] . Furthermore based on the few data available on genetic heterogeneity in hepatocellular adenoma (HCA) when progression to HCC was studied [40] , it can be assumed, that adenoma are more homogeneous. The classification of HCA based on the clinical setting, morphology and genetics is well accepted [6] , and has an impact on the clinical management of HCA patients. For HCC, classification proposals based on genetic changes [26] , or gene expression patterns [41, 42] , have not proven robust enough so far to be integrated into clinical practice. According to our data, intratumor heterogeneity obviously is an obstacle to the establishment of a comprehensive classification of HCC comparable to the HCA classification [6, 7] . Distinct parts of one and the same tumor differ with respect to biomarker expression and mutational status, which illustrates the co-existence of different tumor-cell populations in the same tumor. Presumably, the rate of genetic diversity would be even higher if the genetic analysis of individual tumor areas were expanded to analyze more genes.
Molecular analysis, based on testing a small piece of tumor, might underestimate the complexity of tumor genomics. According to our data which are based on analysis of multiple tumor regions, single tumor biopsies might be an insufficient approach to characterize individual HCC. It is conceivable that a significant proportion of HCC already harbor the same genetic complexity and molecular heterogeneity within one and the same tumor that is characteristic of HCC as a tumor entity [1, 43] . This obviously impedes the development of a comprehensive and clinically meaningful HCC classification.
The level of intratumor heterogeneity we have demonstrated may result in evasion of therapy when targeting single molecules of hepatocarcinogenesis. In particular, the wnt/β-catenin pathway is discussed as a potential therapeutic target in HCC [44] . Since the efficacy of a molecular therapy is determined by the mutational status of the target, e.g. EGFR in colorectal and lung cancer treatment, or c-KIT in the case of GIST, an HCC harboring tumor subpopulations with variable CTNNB1 mutational status (notably prior to therapy) is a major challenge. Currently, treatment with the multi-targeted tyrosine kinase inhibitor sorafenib is the only proposed molecular targeted therapy for HCC, although only a modest survival benefit was demonstrated in a multicenter European HCC trial [45] , and even markedly lower benefit in a trial with Asian HCC patients [46] . The intratumoral molecular diversity we have shown for the TP53 and CTNNB mutational status in a significant proportion of HCC suggests that the development of a molecular targeted therapy for HCC might be more challenging than for tumor entities with more uniform targetable genetic changes.
In summary, in a comprehensive analysis on the level of morphology, immunohistochemistry, and mutational status of TP53 and CTNNB genes, we show that intratumor heterogeneity is a frequent finding in HCC. This finding might be the reason for some of the challenges in developing a robust classification of HCC as well as a molecular targeted therapy for this tumor entity.
